MedTrace Logo

A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients

NCT00445315 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-02-17

Study results available
· View outcomes & findings →

Summary

Assess the safety, tolerability and pharmacokinetics of multiple oral doses of PF-00868554 in HCV positive patient volunteers

Conditions

  • Hepatitis C

Interventions

DRUG

PF-00868554

300 mg BID

DRUG

PF-00868554

450 mg BID

DRUG

PF-00868554

100 mg BID

DRUG

PF-00868554

300 mg TID

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Belgium
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00445315 on ClinicalTrials.gov